$NTRA

Chapman Steven Leonard sold $367K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 1,630 shares of Natera, Inc. (NTRA) at $224.99 ($0.37M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider behavior, but the 10b5-1 designation generally lowers the probability of a fundamental interpretation.

02

Market read

Routine insider selling disclosure; likely sentiment-neutral with limited trading edge unless paired with other catalysts.

03

What to watch

The sale size is relatively small versus typical institutional float; without additional context (e.g., multiple concurrent insider trades), the standalone signal is limited.

Relevance 6/10Novelty 4/10Timing: Filed after-hours/next-day SEC disclosure (June 5 filing; sale dated June 4).

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by Natera’s CEO/President under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera CEO and President Chapman Steven Leonard sold $366,736 of NTRA shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted given the stated 10b5-1 pre-arranged plan.

Evidence & confidence

The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, providing limited incremental information about near-term business prospects.

Market effects

Minimal; single-company insider sale under 10b5-1 typically does not reset sector expectations.

None expected beyond NTRA-specific sentiment.

None expected.

Counterpoint

Even with 10b5-1, repeated insider selling can still coincide with periods of reduced conviction or liquidity needs, potentially capping rallies.

Key entities

  • Natera, Inc.

    Issuer of the Form 4; CEO/President sold shares under a 10b5-1 plan.

  • Chapman Steven Leonard

    CEO and President who executed the reported open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Jim Cramer Calls Natera (NTRA) “a Promising Story”

Natera (NTRA) reported Q2 revenue of $752.8M, up 37.7% YoY, and raised its 2026 revenue forecast. Jim Cramer called it a promising precision medicine platform but advised waiting for a pullback due to valuation concerns. The company faces competition and regulatory risks, with a net loss of $67M in Q2.

$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.